Prestige Biopharma's HD204 Biosimilar Meets Primary Endpoint in Phase 3 NSCLC Trial
核心洞察
Prestige Biopharma (搜索)'s HD204 demonstrated clinical equivalence to Avastin in the Phase 3 SAMSON-II study, meeting the primary endpoint of overall response rate at Week 18 in advanced non-squamous NSCLC patients.
The study enrolled 625 patients across 91 centers in 15 countries, with HD204 achieving a 48.7% response rate compared to 46.5% for Avastin, falling within the predefined equivalence margin.
HD204 showed a safety profile consistent with bevacizumab, with treatment-related adverse events occurring in 33.9% of HD204 patients versus 34.4% of Avastin patients.
Prestige Biopharma (搜索) announced positive topline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin (bevacizumab), in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). The study successfully met its primary endpoint, demonstrating clinical equivalence between HD204 and the reference product.
Study Design and Patient Population
SAMSON-II was conducted as a randomized, double-blind, parallel group, multicenter Phase 3 study across 625 patients at 91 centers in 15 countries. Patients were randomized in a 1:1 ratio to receive either HD204 or Avastin in combination with standard chemotherapy.
Primary Efficacy Results
The study achieved its primary endpoint of overall response rate (ORR) at Week 18, with HD204 demonstrating clinical equivalence to Avastin within the prespecified equivalence margin. The HD204 arm achieved an ORR of 48.7% compared with 46.5% in the Avastin arm. The risk ratio was 1.047 (95% confidence interval [CI]: 0.86–1.27), and the risk difference was 0.022 (95% CI: -0.07–0.11), with both estimates falling within the predefined equivalence range.
Secondary Endpoints and Long-term Outcomes
Secondary efficacy endpoints supported the primary analysis findings. Comparable overall response rates were observed at Week 12 between treatment groups. Time-to-event outcomes demonstrated similar progression-free survival (PFS) and overall survival (OS) between HD204 and Avastin, with no statistically significant differences identified.
Safety and Tolerability Profile
HD204 demonstrated a safety and tolerability profile consistent with the established safety experience of bevacizumab. Treatment-related adverse events were reported in 33.9% of patients receiving HD204 compared to 34.4% of patients receiving Avastin. Treatment-related serious adverse events occurred in 5.2% of HD204 patients and 8.3% of Avastin patients, respectively. No new or unexpected safety signals were identified during the study.
Regulatory and Development Implications
The clinical outcomes observed in SAMSON-II were consistent with the high degree of analytical and clinical pharmacokinetic (PK) similarity previously demonstrated between HD204 and Avastin. These results strengthen the collective global experience showing that sensitive analytical characterization and comparative clinical PK studies can reliably predict equivalent clinical performance in biosimilar development.
Prestige Biopharma (搜索) is advancing regulatory pathways for HD204 based on the strong analytical and clinical PK programs, while sharing the SAMSON-II findings to contribute to the global scientific experience in biosimilar evaluation.
"These results illustrate the increasing precision with which biosimilarity can be established through advanced analytical and clinical PK studies," said Dr. Lisa Park, Chief Executive Officer of Prestige Biopharma (搜索). "Our experience with HD204 supports the view that well-designed development programs can reliably anticipate clinical performance, enabling more focused and efficient biosimilar development. By reducing unnecessary clinical burden, such advances can accelerate patient access to high-quality biologic medicines and support more sustainable healthcare systems worldwide."